Our Work
Latham & Watkins Advises Carlyle on Secondary Offering of QuidelOrtho Corporation Common Stock
November 22, 2024
Capital markets team represents Carlyle as the selling stockholder in the offering by the global provider of innovative in vitro diagnostics technologies.
QuidelOrtho Corporation (Nasdaq: QDEL), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs, and transfusion medicine, closed on November 21, 2024, its previously announced underwritten secondary offering by Carlyle of 8,260,183 shares of the Company’s common stock.
Latham & Watkins LLP represented Carlyle as the selling stockholder in the offering with a capital markets team led by partner Jason Licht, counsel Christopher Cronin, and special legal consultant Maria Concepcion Olivera, with assistance from partner Brian Miller and counsel Jessica Lennon.